Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review
Open Access
- 14 May 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Psychiatry
- Vol. 7 (1), 18
- https://doi.org/10.1186/1471-244x-7-18
Abstract
The efficacy of combined psychotherapy and benzodiazepine treatment for panic disorder is still unclear despite its widespread use. The present systematic review aims to examine its efficacy compared with either monotherapy alone. All randomised trials comparing combined psychotherapy and benzodiazepine for panic disorder with either therapy alone were identified by comprehensive electronic search on the Cochrane Registers, by checking references of relevant studies and of other reviews, and by contacting experts in the field. Two reviewers independently checked eligibility of trials, assessed quality of trials and extracted data from eligible trials using a standardized data extraction form. Our primary outcome was "response" defined by global judgement. Authors of the original trials were contacted for further unpublished data. Meta-analyses were undertaken synthesizing data from all relevant trials. Only two studies, which compared the combination with behaviour (exposure) therapy, met our eligibility criteria. Both studies had a 16-week intervention. Unpublished data were retrieved for one study. The relative risk for response for the combination was 1.25 (95%CI: 0.78 to 2.03) during acute phase treatment, 0.78 (0.45 to 1.35) at the end of treatment, and 0.62 (0.36 to 1.07) at 6–12 months follow-up. Some secondary outcomes hinted at superiority of the combination during acute phase treatment. One study was identified comparing the combination to benzodiazepine. The relative risk for response was 1.57 (0.83 to 2.98), 3.39 (1.03 to 11.21, statistically significant) and 2.31 (0.79 to 6.74) respectively. The superiority of the combination was observed on secondary outcomes at all the time points. No sub-group analyses were conducted due to the limited number of included trials. Unlike some narrative reviews in the literature, our systematic search established the paucity of high quality evidence for or against the combined psychotherapy plus benzodiazepine therapy for panic disorder. Based on limited available published and unpublished data, however, the combined therapy is probably to be recommended over benzodiazepine alone for panic disorder with agoraphobia. The combination might be superior to behaviour therapy alone during the acute phase, but afterwards this trend may be reversed. We know little from these trials about their adverse effects.This publication has 70 references indexed in Scilit:
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatmentBehavior Therapy, 1996
- Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disabilityBehaviour Research and Therapy, 1996
- Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolamJournal of Affective Disorders, 1995
- Alprazolam and Exposure for Panic Disorder with AgoraphobiaThe British Journal of Psychiatry, 1994
- Alprazolam and Exposure Alone and Combined in Panic Disorder with AgoraphobiaThe British Journal of Psychiatry, 1993
- Behaviour Therapy and Benzodiazepines: Allies or Antagonists?The British Journal of Psychiatry, 1990
- The Mobility Inventory for AgoraphobiaBehaviour Research and Therapy, 1985
- Exposure and communications training in the treatment of agoraphobiaBehaviour Research and Therapy, 1982